jRCT2031210447进行中（未招募）不适用
A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy, Safety and PK Study of KX01 Ointment 1% in Japanese Adult Subjects with Actinic Keratosis on the Face or Scalp
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Japanese Males and females >=20 years old who are diagnosed AK by skin biopsy
- •A treatment area on the face or scalp that:
- •(a) is a contiguous area measured 25 square centimeters
- •(b) contains more than 1 clinically typical, visible, and discrete AK lesions
- •Subjects who, in the judgment of the Investigator or Sub-investigator, are in good general health based on:
- •(a) medical history
- •(b) physical examination (PE) findings
- •(c) vital signs
- •(d) ECGs, clinical chemistry, hematology, and urinalysis results
- •Females must be postmenopausal (>45 years of age with at least 12 months of amenorrhea), surgically sterile (by hysterectomy, bilateral oophorectomy, or tubal ligation); or, women with childbearing potential must use highly effective contraception for at least 30 days or 1 menstrual cycle, whichever is longer, prior to sign the informed consent form and must agree to continue to use highly effective contraception for at least 30 days following their last dose of study treatment. Highly effective contraception includes oral hormonal contraceptives, hormonal contraceptive implant, injection or patch, intrauterine device, or complete abstinence from sexual intercourse.
- •Sexually active males who have not had a vasectomy and whose partner is reproductively capable must agree to use barrier contraception from Screening until 90 days after their last dose of study treatment.
- •All subjects must agree not to donate sperm or eggs or attempt conception from Screening until 90 days following their last dose of study treatment.
- •Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1 prior to randomization.
- •Willing to avoid excessive sunlight or ultraviolet (UV) light exposure, including the use of tanning beds, to the face or scalp
- •Able to comprehend and are willing to sign the informed consent form (ICF).
排除标准
- •Clinically atypical and / or rapidly changing AK lesions on the treatment area, e.g., hypertrophic, hyperkeratotic, recalcitrant disease (had cryosurgery on two previous occasions) and / or cutaneous horn
- •Location of the treatment area is:
- •On any location other than the face or scalp
- •Within 5 cm of an incompletely healed wound
- •Within 5 cm of a suspected basal cell carcinoma (BCC) or SCC
- •Been previously treated with KX01 Ointment
- •Anticipated need for in-patient hospitalization or in-patient surgery from Day 1 to Day 57
- •Treatment with 5-fluorouracil (5-FU), imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, or other treatments for AK within the treatment area or within 2 cm of the treatment area, within 8 weeks prior to the Screening visit
- •Use of the following therapies and / or medications within 2 weeks prior to the Screening visit:
- •Cosmetic or therapeutic procedures (e.g., use of liquid nitrogen, surgical excision, curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing) within the treatment area or within 2 cm of the selected treatment area
- •Acid-containing therapeutic products (e.g., salicylic acid or fruit acids, such as alpha- and beta-hydroxyl acids and glycolic acids), topical retinoids, or light chemical peels within the treatment area or within 2 cm of the selected treatment area
- •Topical salves (non-medicated / non-irritant lotion and cream are acceptable) or topical steroids within the treatment area or within 2 cm of the selected treatment area; artificial tanners within the treatment area or within 5 cm of the selected treatment area
- •Use of the following therapies and / or medications within 4 weeks prior to the Screening visit:
- •Treatment with immunomodulators (e.g., azathioprine), cytotoxic drugs (e.g., cyclophosphamide, vinblastine, chlorambucil, methotrexate), or interferons / interferon inducers
- •Treatment with systemic medications that suppress the immune system (e.g., cyclosporine, prednisone, methotrexate, infliximab)
- •Use of systemic retinoids (e.g., bexarotene) within 6 months prior to the Screening visit
- •A history of sensitivity and / or allergy to any of the ingredients in the study medication
- •A skin disease (e.g., atopic dermatitis, psoriasis, eczema) or condition (e.g., scarring, open wounds) that, in the opinion of the Investigator or Sub-investigator, might interfere with the study conduct or evaluations, or which exposes the subject to an unacceptable risk by study participation
- •Other significant uncontrolled or unstable medical diseases or conditions that, in the opinion of the Investigator or Sub-investigator, would expose the subject to an unacceptable risk by study participation
- •Females who are pregnant or nursing
- •Participated in an investigational drug trial during which an investigational study medication was administered within 30 days or 5 half-lives of the investigational product, whichever is longer, before dosing
结局指标
主要结局
-
Safety, e.g. AE, evaluation
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or ScalpActinic KeratosisNCT05231044PharmaEssentia108
已完成
1 期
A phase I clinical study of KSP-0243Healthy ConditionJPRN-jRCT2071200087Shimizu Yoshitaka144
已完成
1 期
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic KeratosisActinic KeratosesNCT03575780Athenex, Inc.18
已完成
2 期
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or ScalpActinic KeratosisNCT02838628Almirall, S.A.168
已完成
3 期
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or ScalpActinic KeratosesNCT03285477Almirall, S.A.351